Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Down 6.38%
As of Friday, October 16, Yarrow Bioscience, Inc.’s YARW share price has dipped by 6.38%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company’s candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Commentary & Analysis
Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Up 6.70%
As of Wednesday, October 07, Yarrow Bioscience, Inc.’s YARW share price has surged by 6.70%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Down 5.02%
As of Tuesday, October 06, Yarrow Bioscience, Inc.’s YARW share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Down 8.67%
As of Monday, October 05, Yarrow Bioscience, Inc.’s YARW share price has dipped by 8.67%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Yarrow Bioscience, Inc.’s (YARW) Stock Is Down 10.15%
As of Monday, October 05, Yarrow Bioscience, Inc.’s YARW share price has dipped by 10.15%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | YARW | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $186.1 | $226.9 | 27% |
|
| Shares Out (Mil) | 4.3 | 53.4 | 13% |
|
| Institutional Ownership | 97.4% | 92.9% | 73% |
|
| Float (Mil) | na | 40.7 | na |
|
| Beta | 2.08 | 0.95 | 92% |
|
| Avg Daily Volume (000s) | 187 | 469 | 45% |
|
| Price Change (52-week) |
na | 46.6% | na |
|
| Growth | YARW | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | YARW | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($284) | ($44) | 5% |
|
| EPS (TTM) | ($66.818) | ($1.600) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | $1 | ($33) | 33% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | na | $174 | na |
|
| Valuation | YARW | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | YARW | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.6% | na |
|
| Net Margin | na | (71.5%) | na |
|
| ROA | na | (47.1%) | na |
|
| ROE | 773.5% | (53.0%) | 100% |
|
| Liabilities to Assets | 5.5% | 29.6% | 3% |
|
| F-Score | 2 | 2 | na |
|
Yarrow Bioscience, Inc. did not pass any screens on 10/30/2026.
